The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Disparity between Ki67 measurements and tumor gene expression tests in patients with hormone-sensitive early breast cancer from the OPTIMA preliminary trial.
 
Robert C. Stein
Stock and Other Ownership Interests - GlaxoSmithKline
 
Andrea Marshall
No Relationships to Disclose
 
Jane Bayani
Honoraria - NanoString Technologies; Thermo Fisher Scientific
Research Funding - Thermo Fisher Scientific
Patents, Royalties, Other Intellectual Property - Invention Disclosure Name: A Molecular Classifier for Personalized Risk Stratification for Patients with Prostate Cancer; Patent (applied): 95-Gene Signature of Residual Risk Following Endocrine Treatment, PCT/CA2016/000304; Patent (applied): Use of Molecular Classifiers to Diagnose, Treat and Prognose Prostate Cancer, US Provisional 63/040.692
 
Andreas Makris
Honoraria - Lilly; NanoString Technologies; Pfizer; Roche
Consulting or Advisory Role - Genzyme; Lilly; Pfizer; Roche
Speakers' Bureau - Lilly; NanoString Technologies; Pfizer; Roche
Travel, Accommodations, Expenses - Roche
 
Iain R. MacPherson
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; Gilead Sciences; In3Bio; Merck Sharp & Dohme (UK) Limited; Pfizer; Roche
Speakers' Bureau - Daiichi Sankyo UK Ltd
Research Funding - Allarity Therapeutics (Inst); AstraZeneca (Inst); Byondis (Inst); Celldex (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Sanofi/Aventis (Inst); Tesaro (Inst)
Travel, Accommodations, Expenses - Daiichi Sankyo; Gilead Sciences; Novartis Pharmaceuticals UK Ltd.
 
Luke Hughes-Davies
No Relationships to Disclose
 
Monika Sobol
No Relationships to Disclose
 
Tammy Piper
No Relationships to Disclose
 
Georgina Dotchin
No Relationships to Disclose
 
Helen Higgins
No Relationships to Disclose
 
Abeer Shaaban
Consulting or Advisory Role - AstraZeneca; Daiitchi Sankyo
Speakers' Bureau - Exact Sciences; Veracyte
 
Sarah E. Pinder
Consulting or Advisory Role - AstraZeneca; Exact Sciences; Roche
Speakers' Bureau - Exact Sciences; Roche
 
Janet Dunn
No Relationships to Disclose
 
John Bartlett
Leadership - MedcomXchange
Honoraria - bioTheranostics; MedcomXchange; NanoString Technologies; Oncology Education
Consulting or Advisory Role - BioNTech; bioTheranostics; Herbert Smith Freehills Paris; Herbert Smith Freehills Paris; Insight Genetics; OncoCyte; oncoXchange; Pfizer; RNA Diagnostics
Research Funding - Agendia; bioTheranostics; Genoptix; NanoString Technologies; Stratifyer GmbH; Thermo Fisher Scientific
Patents, Royalties, Other Intellectual Property - Invention Disclosure Name: A Molecular Classifier for Personalized Risk Stratification for Patients with Prostate Cancer Date: 21/08/2019 (Inst); John Bartlett currently has 1 allowed patent: Jan 2021: Histone gene module predicts anthracycline benefit, PCT/CA2016/000247 (Inst); John Bartlett currently has 5 pending patents: 1. Jan 2017: Methods and Devices for Predicting Anthracycline Treatment Efficacy, US utility – 15/325,472; EPO – 15822898.1; Canada – not yet assigned; 2. Jan 2017: Systems, Devices and Methods for Constructi (Inst)
Travel, Accommodations, Expenses - bioTheranostics; Breast Cancer Society of Canada; NanoString Technologies